Pfizer agreed to pay $67.5 million to settle a class-action lawsuit filed by Wyeth shareholders who claimed they were misled about the risks associated with the antidepressant drug Pristiq (desvenlafaxine). Shareholders alleged that Wyeth’s failure to reveal Pristiq’s adverse cardiovascular and hepatic effects caused the company’s stock price to be inflated between June 2006 and July 2007. The value of the stock dropped more than 10 percent after the company disclosed in July 2007 that the Food and Drug Administration was withholding approval of Pristiq.